{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=56", "query": { "intervention": "serum sample", "page": 56 }, "page_size": 10 }, "pagination": { "page": 56, "page_size": 10, "total_count": 8374, "total_pages": 838, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=57&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=55&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T23:06:22.002Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02156375", "title": "A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 140, "start_date": "2014-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2016-03-22", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 3, "location_summary": "Tempe, Arizona • Lincoln, Nebraska • Neptune City, New Jersey", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02156375" }, { "nct_id": "NCT00576394", "title": "Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glycemic Control" ], "interventions": [ { "name": "IV Insulin drip", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Heart Association", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 108, "start_date": "2006-10", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00576394" }, { "nct_id": "NCT04123795", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate Chronic Plaque Psoriasis", "Severe Chronic Plaque Psoriasis", "Mixed Guttate/Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab pegol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 49, "start_date": "2020-01-21", "completion_date": "2026-07-23", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04123795" }, { "nct_id": "NCT06400472", "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Endometrial Neoplasms", "Uterine Cervical Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Pancreatic Neoplasm", "Colorectal Neoplasms" ], "interventions": [ { "name": "Sofe-M", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 575, "start_date": "2024-05-20", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06400472" }, { "nct_id": "NCT01478477", "title": "Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "omega-3 fatty acid supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Clinical assessments", "type": "OTHER" }, { "name": "Assessment of therapy complications", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Correlative/special studies", "type": "PROCEDURE" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 44, "start_date": "2011-10-04", "completion_date": "2014-01-09", "has_results": false, "last_update_posted_date": "2023-02-27", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478477" }, { "nct_id": "NCT00615056", "title": "A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Bevacizumab (avastin)", "type": "DRUG" }, { "name": "FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])", "type": "DRUG" }, { "name": "AG-013736 (axitinib)", "type": "DRUG" }, { "name": "FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2008-03", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-04-19", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 61, "location_summary": "Mobile, Alabama • Antioch, California • Los Angeles, California + 39 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Antioch", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pleasant Hill", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00615056" }, { "nct_id": "NCT01308931", "title": "The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Birth Control" ], "interventions": [], "intervention_types": [], "sponsor": "Valleywise Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "25 Years to 40 Years · Female only" }, "enrollment_count": 0, "start_date": "2013-01", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2014-08-05", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01308931" }, { "nct_id": "NCT01445405", "title": "Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Squamous", "Head and Neck Cancer", "Oral Cancer", "Laryngeal Cancer", "Pharyngeal Cancer" ], "interventions": [ { "name": "Bortezomib (Velcade, PS-341)", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 3, "start_date": "2008-02-05", "completion_date": "2010-08-27", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445405" }, { "nct_id": "NCT00061594", "title": "A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "rhuFab V2 (ranibizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 426, "start_date": "2003-05", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-03-19", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 70, "location_summary": "Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061594" }, { "nct_id": "NCT06750094", "title": "A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Amivantamab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Leucovorin calcium/Levoleucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2024-12-12", "completion_date": "2029-04-13", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-24T23:06:22.002Z", "location_count": 71, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 60 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06750094" } ] }